Osborne Partners Capital Management LLC Lowers Stock Holdings in SPDR S&P Biotech ETF $XBI

Osborne Partners Capital Management LLC lowered its position in SPDR S&P Biotech ETF (NYSEARCA:XBI) by 5.6% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 170,839 shares of the exchange traded fund’s stock after selling 10,125 shares during the period. SPDR S&P Biotech ETF comprises approximately 1.2% of Osborne Partners Capital Management LLC’s holdings, making the stock its 23rd largest position. Osborne Partners Capital Management LLC owned 0.26% of SPDR S&P Biotech ETF worth $21,821,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the business. Avoro Capital Advisors LLC purchased a new position in shares of SPDR S&P Biotech ETF in the fourth quarter valued at about $256,053,000. Wells Fargo & Company MN boosted its stake in shares of SPDR S&P Biotech ETF by 75.7% in the fourth quarter. Wells Fargo & Company MN now owns 3,566,265 shares of the exchange traded fund’s stock worth $434,835,000 after acquiring an additional 1,536,122 shares during the period. OMERS ADMINISTRATION Corp grew its position in shares of SPDR S&P Biotech ETF by 42,425.2% during the fourth quarter. OMERS ADMINISTRATION Corp now owns 1,190,707 shares of the exchange traded fund’s stock worth $145,147,000 after purchasing an additional 1,187,907 shares in the last quarter. Morgan Stanley raised its stake in SPDR S&P Biotech ETF by 8.3% during the 4th quarter. Morgan Stanley now owns 11,491,683 shares of the exchange traded fund’s stock valued at $1,401,181,000 after purchasing an additional 882,718 shares during the period. Finally, Assetmark Inc. lifted its holdings in SPDR S&P Biotech ETF by 1,042,265.6% in the 4th quarter. Assetmark Inc. now owns 635,843 shares of the exchange traded fund’s stock worth $77,528,000 after purchasing an additional 635,782 shares in the last quarter.

SPDR S&P Biotech ETF Stock Performance

NYSEARCA XBI opened at $160.46 on Friday. SPDR S&P Biotech ETF has a 12 month low of $83.02 and a 12 month high of $160.82. The stock has a market cap of $11.09 billion, a PE ratio of 11.47 and a beta of 0.81. The stock’s 50 day moving average is $137.41 and its 200 day moving average is $129.96.

SPDR S&P Biotech ETF Company Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.